• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).

作者信息

Lip Gregory Y H, Skjøth Flemming, Rasmussen Lars Hvilsted, Nielsen Peter B, Larsen Torben Bjerregaard

出版信息

J Am Coll Cardiol. 2015 Jul 28;66(4):488-90. doi: 10.1016/j.jacc.2015.05.044.

DOI:10.1016/j.jacc.2015.05.044
PMID:26205604
Abstract
摘要

相似文献

1
Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).在具有CHA2DS2-VASc评分（不包括性别）中一项额外危险因素的非瓣膜性房颤患者中，口服抗凝药、阿司匹林或不进行治疗的净临床获益。
J Am Coll Cardiol. 2015 Jul 28;66(4):488-90. doi: 10.1016/j.jacc.2015.05.044.
2
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.非瓣膜性房颤患者，基于 CHA2DS2-VASc 评分，0 或 1 个卒中危险因素，应用口服抗凝药物、阿司匹林或不治疗。
J Am Coll Cardiol. 2015 Apr 14;65(14):1385-94. doi: 10.1016/j.jacc.2015.01.044. Epub 2015 Mar 11.
3
Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?对于 CHA2DS2-VASc 评分（除性别以外）有 1 个额外危险因素的房颤患者，是否应接受口服抗凝治疗？
J Am Coll Cardiol. 2015 Feb 24;65(7):635-42. doi: 10.1016/j.jacc.2014.11.046.
4
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.口服抗凝强度对心房颤动患者卒中严重程度及死亡率的影响。
N Engl J Med. 2003 Sep 11;349(11):1019-26. doi: 10.1056/NEJMoa022913.
5
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Expert Rev Cardiovasc Ther. 2012 Apr;10(4):433-9. doi: 10.1586/erc.12.19.
6
Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.慢性肾脏病行腹膜透析的心房颤动患者的缺血性脑卒中。
Europace. 2016 May;18(5):665-71. doi: 10.1093/europace/euv289. Epub 2015 Oct 25.
7
The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.CHADS2和CHA2DS2-VASc评分对房颤出血风险的预测能力：MAQI(2)研究经验
Thromb Res. 2014 Aug;134(2):294-9. doi: 10.1016/j.thromres.2014.05.034. Epub 2014 Jun 2.
8
Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.心房颤动患者使用新型口服抗凝药时平衡出血与血栓形成风险
Expert Rev Cardiovasc Ther. 2013 Dec;11(12):1619-29. doi: 10.1586/14779072.2013.839214.
9
Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study.年轻心房颤动患者中风的患病率和血栓预防的需求：一项队列研究。
J Cardiovasc Med (Hagerstown). 2014 Mar;15(3):189-93. doi: 10.2459/JCM.0b013e3283654c4b.
10
Clinical inquiries. Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?临床问题。对于非瓣膜性心房颤动患者，联合使用阿司匹林和华法林是否能降低中风风险？
J Fam Pract. 2004 Jul;53(7):570-5.

引用本文的文献

1
Atrial fibrillation: stroke prevention.心房颤动：预防中风。
Lancet Reg Health Eur. 2024 Feb 1;37:100797. doi: 10.1016/j.lanepe.2023.100797. eCollection 2024 Feb.
2
Risk of ischemic stroke and utility of CHA DS -VASc score in women and men with atrial fibrillation.房颤患者中女性与男性的缺血性卒中风险和 CHA2DS2-VASc 评分的实用性。
Clin Cardiol. 2019 Oct;42(10):1003-1009. doi: 10.1002/clc.23257. Epub 2019 Sep 6.
3
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.
房颤抗栓治疗的地域差异：来自 GLORIA-AF II 期注册研究的启示。
Thromb Haemost. 2017 Dec;117(12):2376-2388. doi: 10.1160/TH17-08-0555. Epub 2017 Dec 6.
4
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.亚太心脏节律学会2017年心房颤动卒中预防共识
J Arrhythm. 2017 Aug;33(4):345-367. doi: 10.1016/j.joa.2017.05.004. Epub 2017 Jun 27.
5
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.伴有单一卒中危险因素的房颤患者中标准剂量非维生素 K 拮抗剂口服抗凝剂和华法林的有效性和安全性：一项全国性队列研究。
JAMA Cardiol. 2017 Aug 1;2(8):872-881. doi: 10.1001/jamacardio.2017.1883.
6
Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study.根据不同指南治疗阈值的心房颤动患者中风和血栓栓塞事件发生率：一项全国性队列研究。
Sci Rep. 2016 Jun 6;6:27410. doi: 10.1038/srep27410.
7
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.选择特定的口服抗凝药物和剂量预防非瓣膜性心房颤动患者卒中：第 1 部分。
Eur Heart J. 2017 Mar 21;38(12):852-859. doi: 10.1093/eurheartj/ehv643.